Program
Treatment A: BGF MDI HFO
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 20 open or running | phase 1since Oct 4, 2022 | Oct 4, 2022 | none ahead |
Also a collaborator on its studies: Parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 4, 2022First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT05569421 · 108 enrolled · United States
- Dec 4, 2024Phase 1 study in AsthmaNCT06723756 · 105 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06723756Asthma · United States | 1 | Completed | Jun 1, 2025 | 105 |
| NCT05569421Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | Apr 14, 2023 | 108 |
How it is read
Names in the registry
- “Treatment A: BGF MDI HFO”, 2 entries
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 1 study
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.